Full-Time

Vice President – Global Medical Lead

Confirmed live in the last 24 hours

Relay Therapeutics

Relay Therapeutics

201-500 employees

Biotech company focused on drug discovery

Biotechnology
Healthcare

Senior

Cambridge, MA, USA

Category
Physicians & Surgeons
Medical, Clinical & Veterinary
Requirements
  • You have earned an MD (or equivalent degree) with oncology experience, and preferably are an oncologist
  • You have experience clinical and/or development experience in advanced breast cancer, preferably with existing relationships with global disease experts
  • You know what successful small molecule development looks like and you bring 6+ years of industry experience in late-stage clinical development, preferably through registration
  • You have experience developing targeted oncology products in molecularly selected patient populations.
  • You have experience in design and execution of innovative late phase clinical trials including design and development of clinical protocols and statistical analysis plans.
  • You have outstanding interpersonal and communication skills both written and oral and ability to communicate complex information clearly and succinctly.
  • You have excellent leadership skills and proven ability to effectively work in a cross-functional/matrix environment.
  • You know how to work collaboratively with experts and leaders across Research, Pharmaceutical Development, Clinical, Regulatory and Strategy & Operations.
  • You have an unwavering commitment to help patients who suffer from debilitating diseases.
Responsibilities
  • Drive forward the clinical strategy and study design and oversee execution of pivotal clinical development to registration of RLY-2608 in second line HR+ HER2- advanced breast cancer, in collaboration with clinical operations, clinical science, biostatistics, regulatory, medical affairs, disease-specific experts and Phase 3 investigators
  • Collaborate with early clinical development, translational medicine, biology, pharmacology and new product planning to develop novel combinations with RLY-2608 for indication expansion in breast cancer, including earlier lines of therapy and other subtypes of breast cancer, as well as potential novel assets in breast cancer
  • Lead authoring of clinical sections of key documents, including Investigator’s Brochures, CTAs for initiation of ex-US studies and responses to questions from regulatory authorities, IRBs, and ethics committees and Clinical Study Reports.
  • Inform global registration strategy by providing expert medical review, assessment, and interpretation of clinical data and preparing results for presentation to regulatory authorities.
  • Oversee drug safety and pharmacovigilance activities for ongoing trial(s).
  • Rapidly integrate new insights derived from on-going Relay Tx or external clinical trials, translational science or basic science into Relay Tx development plans and clinical trial activities.
  • Create compelling data presentations for external disclosures.
  • Proactively manage communication and build strong collaborative relationships with key stakeholders both internally and externally, including interactions with academic experts, clinical trial investigators, and other clinical stakeholders.
  • Ensure Relay Tx maintains the highest standards of compliance and ethical behavior in the design, conduct, interpretation and communication of clinical trials, clinical trial data, and clinical trial results.

Relay Therapeutics focuses on drug discovery by studying protein motion to develop new treatments for complex diseases. Their main tool, the Dynamo™ platform, uses both experimental and computational methods to identify potential drug candidates, especially for hard-to-target proteins. This approach allows them to explore new treatment options in areas like precision oncology and genetic diseases. Unlike other companies, Relay Therapeutics emphasizes the importance of protein dynamics in their research, which sets them apart in the biotech field. Their goal is to create effective medicines that can significantly improve patients' lives, and they are currently conducting clinical trials to ensure the safety and effectiveness of their drug candidates.

Company Stage

IPO

Total Funding

$535M

Headquarters

Cambridge, Massachusetts

Founded

2016

Growth & Insights
Headcount

6 month growth

-6%

1 year growth

-12%

2 year growth

-8%
Simplify Jobs

Simplify's Take

What believers are saying

  • Relay's focus on precision oncology and genetic diseases positions it at the forefront of personalized medicine, offering significant growth potential.
  • Recent investments and financing, including a $30 million private placement and $400 million Series C financing, indicate strong financial backing and investor confidence.
  • Initial clinical data for RLY-2608 and other promising drug candidates highlight the company's potential for successful therapeutic developments.

What critics are saying

  • The highly competitive biotech sector requires continuous innovation to maintain a leading position.
  • Dependence on strategic partnerships and licensing agreements could pose risks if collaborations do not yield expected results.

What makes Relay Therapeutics unique

  • Relay Therapeutics places protein motion at the core of its drug discovery process, a unique approach that sets it apart from traditional methods.
  • The Dynamo™ platform combines experimental and computational techniques to target previously undruggable proteins, expanding treatment possibilities.
  • Strategic collaborations, such as the one with Genentech, validate the potential of Relay's innovative technology and approach.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Medical, dental, vision

Life, disability, & FSA

401k

Commuter benefits

Parental leave

Home office stipend

Tuition reimbursement

PTO